Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors
Authors
Keywords
-
Journal
Cells
Volume 11, Issue 1, Pages 9
Publisher
MDPI AG
Online
2021-12-21
DOI
10.3390/cells11010009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of Proteasomes in Inflammation
- (2021) Carl Christoph Goetzke et al. Journal of Clinical Medicine
- POS0695 KZR-616, A SELECTIVE IMMUNOPROTEASOME INHIBITOR FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE COMPLETED DOSE ESCALATION PHASE 1B PORTION OF THE MISSION STUDY
- (2021) R. Furie et al. ANNALS OF THE RHEUMATIC DISEASES
- Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the Immunoproteasome
- (2021) Ying Fang et al. DRUG METABOLISM AND DISPOSITION
- Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)
- (2021) Markus Klein et al. JOURNAL OF MEDICINAL CHEMISTRY
- M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models
- (2021) Michael P. Sanderson et al. MOLECULAR CANCER THERAPEUTICS
- Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein
- (2021) Tyler W. Jenkins et al. Scientific Reports
- A Nut for Every Bolt: Subunit-Selective Inhibitors of the Immunoproteasome and Their Therapeutic Potential
- (2021) Eva M. Huber et al. Cells
- Immunoproteasome Function in Normal and Malignant Hematopoiesis
- (2021) Nuria Tubío-Santamaría et al. Cells
- Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism
- (2021) Jinhai Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors
- (2019) Jun Li et al. KIDNEY INTERNATIONAL
- Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
- (2019) Pawel Robak et al. Drugs in research & development
- Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience
- (2019) A Segarra et al. LUPUS
- The immunoproteasome‐specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis
- (2018) Nadine Althof et al. EMBO Molecular Medicine
- Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors
- (2018) Tobias Alexander et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation
- (2018) Jun Li et al. KIDNEY INTERNATIONAL
- Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus
- (2018) Tomonori Ishii et al. Modern Rheumatology
- Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity
- (2018) Michael Basler et al. EMBO REPORTS
- Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)
- (2018) Henry W. B. Johnson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
- (2017) C S Chim et al. LEUKEMIA
- The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis
- (2017) H Zhang et al. LUPUS
- Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder
- (2017) Chao Zhang et al. JAMA Neurology
- Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
- (2016) Susan J. Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells
- (2016) Joel D. Federspiel et al. MOLECULAR & CELLULAR PROTEOMICS
- Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice
- (2016) Esilida Sula Karreci et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Perspective on the Kinetics of Covalent and Irreversible Inhibition
- (2016) John M. Strelow SLAS Discovery
- The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
- (2015) Tobias Alexander et al. ANNALS OF THE RHEUMATIC DISEASES
- Inhibition and deficiency of the immunoproteasome subunit LMP7 attenuates LCMV-induced meningitis
- (2015) Sarah Mundt et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Bortezomib for Refractory Autoimmunity in Pediatrics
- (2014) Pooja Khandelwal et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome
- (2014) Hao Fan et al. ACS Medicinal Chemistry Letters
- Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors
- (2013) D. Niewerth et al. HAEMATOLOGICA
- Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
- (2012) Eva M. Huber et al. CELL
- Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
- (2012) Alexei F. Kisselev et al. CHEMISTRY & BIOLOGY
- Immunoproteasome Subunit LMP7 Deficiency and Inhibition Suppresses Th1 and Th17 but Enhances Regulatory T Cell Differentiation
- (2012) K. W. Kalim et al. JOURNAL OF IMMUNOLOGY
- Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells
- (2011) H. Travis Ichikawa et al. ARTHRITIS AND RHEUMATISM
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- The Antiviral Immune Response in Mice Devoid of Immunoproteasome Activity
- (2011) M. Basler et al. JOURNAL OF IMMUNOLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma
- (2010) K. Frohlich et al. ANNALS OF THE RHEUMATIC DISEASES
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
- (2009) F. Parlati et al. BLOOD
- Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
- (2009) Han-Jie Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
- (2009) Tony Muchamuel et al. NATURE MEDICINE
- The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
- (2008) Kirsten Neubert et al. NATURE MEDICINE
- Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
- (2008) Matthew J. Everly et al. TRANSPLANTATION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started